Skip to main content

COVID-19 Impact ON Genotyping Assay Market (2018-2023) Country Level Analysis, Current Trade Size And Future Prospective

The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.

  • MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period.



The study involved four major activities to estimate the current market size for particle therapy. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.

The major factors that are expected to be driving the Genotyping Assay market are technological advancements and the decreasing prices of DNA sequencing.

Browse 219 market data Tables and 53 Figures spread through 280 Pages
Download PDF Brochure Now:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

Application of Genotyping assay market:

1. Pharmacogenomics
2. Diagnostic Research
3. Animal Genetics
4. bioinformatics
5. Agricultural Biotechnology

The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.

By technology, the sequencing segment to record the highest CAGR during the forecast period
The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.

The report claims to split the Regional Scope of the Genotyping assay market into

  • North America (US and Canada)
  • Europe (Germany, France, UK, Spain, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan,  India and ASEAN)
  • Rest of World (Latin America, Middle East & Africa)

Regional Growth, Development and Demand Analysis:

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada.

 Key Players:

Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Illumina is the leading player in the genotyping market. The company led the sequencing market with its flagship NGS platforms—iSeq 100 system (launched in January 2018), NovaSeq 6000, HiSeq Series, MiSeq Series, NextSeq 500, and HiSeq X Ten & HiSeq X Five.

Request Sample Report of Genotyping Market: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595
Labels:

Comments

Post a Comment

Popular posts from this blog

Autoinjectors Market | Newest Industry Data, Future Trends and Forecast 2023

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs. The  global autoinjectors market  is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). In terms of Therapy, the global autoinjectors market can be segmented into: Rheumatoid Arthritis Multiple Sclerosis Diabetes Anaphylaxis Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia) By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therap...
Post a Comment
Read more

Healthcare BPO Market To Reach $312.43 Billion By 2022 : Increasing Consolidation In The Healthcare Industry

  What This Report Will Provide? In the current market scenario, there is a growing demand for healthcare BPO services. The objective of this report is to define, describe, and forecast the market on the basis of outsourcing services including payer, provider, and pharmaceutical services and region. It provides detailed information regarding the major factors influencing the growth of healthcare outsourcing market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials. Expected Revenue Growth: Healthcare BPO market  is estimated to grow at a CAGR of 10.2% from 2017 to 2022 to reach $312.43 billion by 2022 from $191.68 billion in 2017. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Major Growth Boosters: Patent cliffs, complex clinical trial protocols, and new reporting requirements are forcing pha...
Post a Comment
Read more

North American Nuclear Medicine Market To Reach USD 2.7 Billion By 2024 – Expansion In Emerging Economies

  What This Report Will Provide? The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Expected Revenue Growth: [159 Pages Report] The  North American nuclear medicine market  is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. Major Growth Boosters: Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment...
Post a Comment
Read more